RU2393720C2 - Пищевой и/или фармацевтический препарат для применения в профилактике и лечении нарушений абсорбции микроэлементов из пищеварительного тракта - Google Patents

Пищевой и/или фармацевтический препарат для применения в профилактике и лечении нарушений абсорбции микроэлементов из пищеварительного тракта Download PDF

Info

Publication number: RU2393720C2
Authority: RU; Russia
Prior art keywords: glutamine; alpha; absorption; subject; manganese
Prior art date: 2004-10-29

Application number

RU2007115542/15A

Other languages

English (en)

Russian (ru)

Other versions

RU2007115542A (ru

Inventor

Стефан ПЕРЗИНОВСКИ (SE)

Стефан ПЕРЗИНОВСКИ

Лукаш ПЕРЗИНОВСКИ (PL)

Лукаш ПЕРЗИНОВСКИ

Кацпер ПЕРЗИНОВСКИ (PL)

Кацпер ПЕРЗИНОВСКИ

Original Assignee

СГП энд Санс АБ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-29

Filing date

2005-10-28

Publication date

2010-07-10

2005-10-28 Application filed by СГП энд Санс АБ filed Critical СГП энд Санс АБ

2008-12-10 Publication of RU2007115542A publication Critical patent/RU2007115542A/ru

2010-07-10 Application granted granted Critical

2010-07-10 Publication of RU2393720C2 publication Critical patent/RU2393720C2/ru

Links

238000010521 absorption reaction Methods 0.000 title claims abstract description 23
235000013305 food Nutrition 0.000 title claims abstract description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 12
230000002496 gastric effect Effects 0.000 title abstract 4
230000000069 prophylactic effect Effects 0.000 title description 5
208000035475 disorder Diseases 0.000 title description 2
239000008177 pharmaceutical agent Substances 0.000 title 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 28
KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 14
150000003839 salts Chemical class 0.000 claims abstract description 12
239000011572 manganese Substances 0.000 claims abstract description 11
229910052742 iron Inorganic materials 0.000 claims abstract description 10
206010028980 Neoplasm Diseases 0.000 claims abstract description 9
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 8
210000004185 liver Anatomy 0.000 claims abstract description 8
229910052748 manganese Inorganic materials 0.000 claims abstract description 8
239000011701 zinc Substances 0.000 claims abstract description 7
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 6
229910052725 zinc Inorganic materials 0.000 claims abstract description 6
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 5
239000011575 calcium Substances 0.000 claims abstract description 5
229910052802 copper Inorganic materials 0.000 claims abstract description 5
239000010949 copper Substances 0.000 claims abstract description 5
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims abstract description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052791 calcium Inorganic materials 0.000 claims abstract description 4
229910052712 strontium Inorganic materials 0.000 claims abstract description 4
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims abstract description 4
230000004064 dysfunction Effects 0.000 claims description 14
239000011573 trace mineral Substances 0.000 claims description 12
235000013619 trace mineral Nutrition 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 10
241000282887 Suidae Species 0.000 claims description 9
210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
230000000968 intestinal effect Effects 0.000 claims description 9
210000003205 muscle Anatomy 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
230000001580 bacterial effect Effects 0.000 claims description 7
230000003247 decreasing effect Effects 0.000 claims description 7
206010066468 Anaemia of pregnancy Diseases 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 6
206010012289 Dementia Diseases 0.000 claims description 6
206010017533 Fungal infection Diseases 0.000 claims description 6
208000031888 Mycoses Diseases 0.000 claims description 6
208000001132 Osteoporosis Diseases 0.000 claims description 6
208000003217 Tetany Diseases 0.000 claims description 6
208000036142 Viral infection Diseases 0.000 claims description 6
206010003246 arthritis Diseases 0.000 claims description 6
230000036039 immunity Effects 0.000 claims description 6
-1 iron ions Chemical class 0.000 claims description 6
230000003612 virological effect Effects 0.000 claims description 6
208000035143 Bacterial infection Diseases 0.000 claims description 5
241000283690 Bos taurus Species 0.000 claims description 5
241000283707 Capra Species 0.000 claims description 5
241000283086 Equidae Species 0.000 claims description 5
241001494479 Pecora Species 0.000 claims description 5
208000022362 bacterial infectious disease Diseases 0.000 claims description 5
230000000747 cardiac effect Effects 0.000 claims description 5
229910021645 metal ion Inorganic materials 0.000 claims description 5
210000000941 bile Anatomy 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000005856 abnormality Effects 0.000 claims description 3
210000001519 tissue Anatomy 0.000 claims description 3
239000002872 contrast media Substances 0.000 claims description 2
238000003745 diagnosis Methods 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
241000271566 Aves Species 0.000 claims 1
241001465754 Metazoa Species 0.000 abstract description 33
230000000694 effects Effects 0.000 abstract description 5
239000000126 substance Substances 0.000 abstract description 4
239000003795 chemical substances by application Substances 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 59
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 56
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 56
235000004554 glutamine Nutrition 0.000 description 56
229960002743 glutamine Drugs 0.000 description 56
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 37
229930195712 glutamate Natural products 0.000 description 36
235000001014 amino acid Nutrition 0.000 description 34
150000001413 amino acids Chemical class 0.000 description 34
HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 30
229940009533 alpha-ketoglutaric acid Drugs 0.000 description 30
210000004369 blood Anatomy 0.000 description 21
239000008280 blood Substances 0.000 description 21
108010016626 Dipeptides Proteins 0.000 description 16
239000000825 pharmaceutical preparation Substances 0.000 description 13
SLPUVFBNQHVEEU-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid;2-oxopentanedioic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CCC(=O)C(O)=O SLPUVFBNQHVEEU-WCCKRBBISA-N 0.000 description 12
229940075858 ornithine alpha-ketoglutarate Drugs 0.000 description 12
238000001802 infusion Methods 0.000 description 11
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
230000037396 body weight Effects 0.000 description 8
210000000936 intestine Anatomy 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
210000001198 duodenum Anatomy 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
206010016717 Fistula Diseases 0.000 description 4
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 4
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 4
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
229910021529 ammonia Inorganic materials 0.000 description 4
210000001842 enterocyte Anatomy 0.000 description 4
229960003104 ornithine Drugs 0.000 description 4
150000005693 branched-chain amino acids Chemical class 0.000 description 3
235000003642 hunger Nutrition 0.000 description 3
210000001630 jejunum Anatomy 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
235000016236 parenteral nutrition Nutrition 0.000 description 3
210000003240 portal vein Anatomy 0.000 description 3
244000144977 poultry Species 0.000 description 3
239000002243 precursor Substances 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002729 catgut Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
230000003890 fistula Effects 0.000 description 2
238000002695 general anesthesia Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-M glutamate Chemical compound [O-]C(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-M 0.000 description 2
229940049906 glutamate Drugs 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
238000007833 oxidative deamination reaction Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
208000035944 Duodenal fistula Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000008081 Intestinal Fistula Diseases 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
206010025476 Malabsorption Diseases 0.000 description 1
208000004155 Malabsorption Syndromes Diseases 0.000 description 1
102000036675 Myoglobin Human genes 0.000 description 1
108010062374 Myoglobin Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000032823 cell division Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
150000002308 glutamine derivatives Chemical class 0.000 description 1
102000005396 glutamine synthetase Human genes 0.000 description 1
108020002326 glutamine synthetase Proteins 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
PQQAOTNUALRVTE-UHFFFAOYSA-L iron(2+);diformate Chemical compound [Fe+2].[O-]C=O.[O-]C=O PQQAOTNUALRVTE-UHFFFAOYSA-L 0.000 description 1
ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
229940039412 ketalar Drugs 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000006609 metabolic stress Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
210000000323 shoulder joint Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Polymers & Plastics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Food Science & Technology (AREA)
Immunology (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Animal Husbandry (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Reproductive Health (AREA)
Obesity (AREA)

RU2007115542/15A 2004-10-29 2005-10-28 Пищевой и/или фармацевтический препарат для применения в профилактике и лечении нарушений абсорбции микроэлементов из пищеварительного тракта RU2393720C2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PL370937A PL370937A1 (pl)	2004-10-29	2004-10-29	Preparat żywieniowy i/lub farmaceutyczny do stosowania w profilaktyce i leczeniu niedoborów wchłaniania mikroelementów z przewodu pokarmowego oraz zastosowanie preparatu farmaceutycznego jako czynnika stymulującego wchłanianie mikroelementów z przewodu pokarmowego do krwi
PLP370937		2004-10-29

Publications (2)

Publication Number	Publication Date
RU2007115542A RU2007115542A (ru)	2008-12-10
RU2393720C2 true RU2393720C2 (ru)	2010-07-10

Family

ID=35601796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2007115542/15A RU2393720C2 (ru)	2004-10-29	2005-10-28	Пищевой и/или фармацевтический препарат для применения в профилактике и лечении нарушений абсорбции микроэлементов из пищеварительного тракта

Country Status (12)

Country	Link
US (1)	US20090238895A1 (fr)
EP (1)	EP1806983B8 (fr)
JP (1)	JP4960872B2 (fr)
KR (1)	KR20070117534A (fr)
CN (1)	CN101048081B (fr)
AT (1)	ATE394942T1 (fr)
AU (1)	AU2005300125B2 (fr)
CA (1)	CA2589324A1 (fr)
DE (1)	DE602005006831D1 (fr)
PL (1)	PL370937A1 (fr)
RU (1)	RU2393720C2 (fr)
WO (1)	WO2006046880A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA018554B1 (ru) *	2007-07-02	2013-08-30	Энтресс Аб	Применение альфа-кетоглутаровой кислоты и ее солей для улучшения эластичности кровеносных сосудов
ITBO20120226A1 (it)	2012-04-24	2013-10-25	Alfa Wassermann Spa	Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
KR101699123B1 (ko) *	2013-07-22	2017-01-24	경상대학교산학협력단	코르티코스테론 저하용 조성물
CN104146271A (zh) *	2014-08-27	2014-11-19	何瑞红	调节代谢、保护肝脏的营养补充剂及其制备方法和应用
JP7122018B2 (ja) *	2017-09-15	2022-08-19	カインサイエンスシーオー．，エルティーディー．	自己免疫疾患および骨疾患の治療剤としてのペプチドの用途
EP3888471A4 (fr) *	2018-12-18	2021-12-22	Peng, Xianfeng	Application d'un dérivé de glutamine dans la préparation d'un additif alimentaire pour animaux
CN111820330A (zh) *	2020-07-17	2020-10-27	禹城保立康生物饲料有限公司	一种提高哺乳仔猪发育的母猪饲料

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1153634A (zh) *	1995-12-05	1997-07-09	孔彦平	一种防治钙质缺损的药物及其制备方法
WO2003043626A1 (fr) *	2001-11-23	2003-05-30	Essentys Ab	Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose
WO2003055508A1 (fr) *	2001-12-21	2003-07-10	Essentys Ab	Composition pour le traitement d'insuffisance renale ou de dysfonctionnement gastrique, par exemple chez les mammiferes prematures ou nouveau-nes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4830716B1 (en) *	1986-07-03	1999-12-07	Albion Int	Preparation of pharmaceutical grade amino acid chelates
EP0607278B1 (fr) *	1991-10-07	2002-04-17	The Brigham And Women's Hospital, Inc.	Procede permettant d'ameliorer l'absorption intestinale
JP3232718B2 (ja) *	1992-03-24	2001-11-26	味の素株式会社	易吸収性ミネラル含有組成物及びそれを含有する飲食品
US5292538A (en) *	1992-07-22	1994-03-08	Metagenics, Inc.	Improved sustained energy and anabolic composition and method of making
US5270297A (en) *	1992-07-23	1993-12-14	Metagenics, Inc.	Endurance and rehydration composition
GB9619758D0 (en) *	1996-09-23	1996-11-06	Nycomed Imaging As	Method
ATE342722T1 (de) *	2003-05-07	2006-11-15	Osteologix As	Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen

2004
- 2004-10-29 PL PL370937A patent/PL370937A1/pl not_active Application Discontinuation
2005
- 2005-10-28 AU AU2005300125A patent/AU2005300125B2/en not_active Ceased
- 2005-10-28 AT AT05799655T patent/ATE394942T1/de not_active IP Right Cessation
- 2005-10-28 EP EP05799655A patent/EP1806983B8/fr not_active Expired - Lifetime
- 2005-10-28 US US11/577,892 patent/US20090238895A1/en not_active Abandoned
- 2005-10-28 CA CA002589324A patent/CA2589324A1/fr not_active Abandoned
- 2005-10-28 KR KR1020077011918A patent/KR20070117534A/ko not_active Abandoned
- 2005-10-28 JP JP2007538850A patent/JP4960872B2/ja not_active Expired - Fee Related
- 2005-10-28 CN CN2005800372304A patent/CN101048081B/zh not_active Expired - Fee Related
- 2005-10-28 DE DE602005006831T patent/DE602005006831D1/de not_active Expired - Lifetime
- 2005-10-28 RU RU2007115542/15A patent/RU2393720C2/ru not_active IP Right Cessation
- 2005-10-28 WO PCT/PL2005/000068 patent/WO2006046880A1/fr not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1153634A (zh) *	1995-12-05	1997-07-09	孔彦平	一种防治钙质缺损的药物及其制备方法
WO2003043626A1 (fr) *	2001-11-23	2003-05-30	Essentys Ab	Utilisation de glutamate, de metabolites ou de derives du glutamate, d'analogues du glutamate ou de melanges de ceux-ci pour preparer une composition destinee au traitement de l'osteoporose
WO2003055508A1 (fr) *	2001-12-21	2003-07-10	Essentys Ab	Composition pour le traitement d'insuffisance renale ou de dysfonctionnement gastrique, par exemple chez les mammiferes prematures ou nouveau-nes

Also Published As

Publication number	Publication date
WO2006046880A1 (fr)	2006-05-04
EP1806983A1 (fr)	2007-07-18
JP4960872B2 (ja)	2012-06-27
US20090238895A1 (en)	2009-09-24
ATE394942T1 (de)	2008-05-15
EP1806983B8 (fr)	2009-02-18
KR20070117534A (ko)	2007-12-12
EP1806983B1 (fr)	2008-05-14
CA2589324A1 (fr)	2006-05-04
RU2007115542A (ru)	2008-12-10
AU2005300125B2 (en)	2011-07-14
JP2008518002A (ja)	2008-05-29
PL370937A1 (pl)	2006-05-02
DE602005006831D1 (de)	2008-06-26
CN101048081A (zh)	2007-10-03
CN101048081B (zh)	2011-05-18
HK1109029A1 (en)	2008-05-30
AU2005300125A1 (en)	2006-05-04

Publication	Publication Date	Title
RU2444355C2 (ru)	2012-03-10	Способы лечения с применением цитруллина
KR102057555B1 (ko)	2019-12-19	신부전 환자를 치료하기 위한 카복실산 혼합물
JP6172724B2 (ja)	2017-08-02	免疫寛容の誘導促進剤
CN110339207B (zh)	2022-08-05	抗癌剂的副作用的预防剂和/或治疗剂
RU2393720C2 (ru)	2010-07-10	Пищевой и/или фармацевтический препарат для применения в профилактике и лечении нарушений абсорбции микроэлементов из пищеварительного тракта
RU2351323C2 (ru)	2009-04-10	Способ получения комплексного препарата для профилактики и лечения нарушений обмена веществ, микроэлементозов, повышения резистентности организма животных
HK1200323A1 (en)	2015-08-07	Anemia of cancer improving / prophylactic agent
EA015078B1 (ru)	2011-04-29	Препарат и способ профилактики и коррекции патологических состояний животных
RU2402320C1 (ru)	2010-10-27	Препарат и способ профилактики и коррекции патологических состояний животных на его основе
RU2052266C1 (ru)	1996-01-20	Способ лечения гепатоза коров
RU2721605C1 (ru)	2020-05-21	Фармацевтическая композиция для парентерального капельного введения
HK1109029B (en)	2011-12-16	Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal
RU2343906C2 (ru)	2009-01-20	Способ коррекции и профилактики патологических состояний животных
JPH02306914A (ja)	1990-12-20	癌用アミノ酸製剤
JPH0710770A (ja)	1995-01-13	アミノ酸輸液
RU2720134C1 (ru)	2020-04-24	Фармацевтическая композиция для парентерального капельного введения
TW202308626A (zh)	2023-03-01	降脂促進劑
RU2229883C2 (ru)	2004-06-10	Способ лечения и профилактики диспепсии телят, поросят
RU2279881C1 (ru)	2006-07-20	Способ предоперационной эндоскопической подготовки деринатом больных с осложненной язвенной болезнью двенадцатиперстной кишки
JP2022080787A (ja)	2022-05-30	アルツハイマー病様症状緩和剤
HK1194993B (en)	2018-09-21	Prophylactic agent and/or therapeutic agent for sepsis
HK1194993A (en)	2014-10-31	Prophylactic agent and/or therapeutic agent for sepsis
UA141863U (uk)	2020-04-27	Застосування інфузійного препарату реосорбілакт для нормалізації активності амінотрансфераз крові в оперованих хворих на рак кардіального відділу шлунка після проксимальної резекції шлунка
Sahatrakul et al.	2015	Successful treatment of sepsis using combined intravenous and oral administration of antibiotics in a Zebra Bullhead Shark (Heterodontus zebra) at the SEA Aquarium, RWS: a case report.
HK1226665A1 (en)	2017-10-06	Enhancer of survival of transplanted organ

Legal Events

Date	Code	Title	Description
2015-08-20	MM4A	The patent is invalid due to non-payment of fees	Effective date: 20141029